MONTREAL, QUEBEC--(MARKET WIRE)--Jun 4, 2007 -- MethylGene Inc. (Toronto:MYG.TO - News), along with its collaborators Pharmion Corporation (NasdaqGM:PHRM - News) and Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan), today provided an update on its clinical trials with its lead oncology product candidate MGCD0103, a novel isotype-selective histone deacetylase (HDAC) inhibitor. Data for this compound was recently presented at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
